从干血斑标本中监测艾滋病毒耐药性突变的内部有效检测方法

IF 2.2 4区 医学 Q3 BIOCHEMICAL RESEARCH METHODS
Bronwyn Neufeld , Chantal Munyuza , Alexandria Reimer , Rupert Capiña , Emma R. Lee , Marissa Becker , Paul Sandstrom , Hezhao Ji , François Cholette
{"title":"从干血斑标本中监测艾滋病毒耐药性突变的内部有效检测方法","authors":"Bronwyn Neufeld ,&nbsp;Chantal Munyuza ,&nbsp;Alexandria Reimer ,&nbsp;Rupert Capiña ,&nbsp;Emma R. Lee ,&nbsp;Marissa Becker ,&nbsp;Paul Sandstrom ,&nbsp;Hezhao Ji ,&nbsp;François Cholette","doi":"10.1016/j.jviromet.2024.114939","DOIUrl":null,"url":null,"abstract":"<div><p>Despite increasing scale-up of antiretroviral therapy (ART) coverage, challenges related to adherence and HIV drug resistance (HIVDR) remain. The high cost of HIVDR surveillance is a persistent challenge with implementation in resource-constrained settings. Dried blood spot (DBS) specimens have been demonstrated to be a feasible alternative to plasma or serum for HIVDR genotyping and are more suitable for lower resource settings. There is a need for affordable HIVDR genotyping assays which can amplify HIV-1 sequences from DBS specimens, particularly those with low viral loads, at a low cost. Here, we present an in-house assay capable of reliably amplifying HIV-1 protease and partial reverse transcriptase genes from DBS specimens, which covers the complete World Health Organization 2009 list of drug resistance mutations under surveillance. DBS specimens were prepared using whole blood spiked with HIV-1 at concentrations of 10,000, 5000, 1000, and 500 copies/mL (n=30 for each concentration). Specimens were tested in triplicate. A two-step approach was used consisting of cDNA synthesis followed by nested PCR. The limit of detection of the assay was calculated to be approximately 5000 (95<!--> <!-->% CI: 3200–10,700) copies/mL for the protease gene and 3600 (95<!--> <!-->% CI: 2200–10,000) copies/mL for reverse transcriptase. The assay was observed to be most sensitive with higher viral load specimens (97.8<!--> <!-->% [95<!--> <!-->% CI: 92.2–99.7]) for both protease and reverse transcriptase at 10,000 copies/mL with performance decreasing with the use of specimens with lower viral loads (46.7<!--> <!-->% [36.1–57.5] and 60.0<!--> <!-->% [49.1–70.2] at 500 copies/mL for protease and reverse transcriptase, respectively). Ultimately, this assay presents a promising opportunity for use in resource-constrained settings. Future work should involve validation under field conditions including sub-optimal storage conditions and preparation of DBS with fingerprick blood in order to accurately reflect real-world collection scenarios.</p></div>","PeriodicalId":17663,"journal":{"name":"Journal of virological methods","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0166093424000636/pdfft?md5=33d7e82bc47839f120e0a31109768c20&pid=1-s2.0-S0166093424000636-main.pdf","citationCount":"0","resultStr":"{\"title\":\"A validated in-house assay for HIV drug resistance mutation surveillance from dried blood spot specimens\",\"authors\":\"Bronwyn Neufeld ,&nbsp;Chantal Munyuza ,&nbsp;Alexandria Reimer ,&nbsp;Rupert Capiña ,&nbsp;Emma R. Lee ,&nbsp;Marissa Becker ,&nbsp;Paul Sandstrom ,&nbsp;Hezhao Ji ,&nbsp;François Cholette\",\"doi\":\"10.1016/j.jviromet.2024.114939\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Despite increasing scale-up of antiretroviral therapy (ART) coverage, challenges related to adherence and HIV drug resistance (HIVDR) remain. The high cost of HIVDR surveillance is a persistent challenge with implementation in resource-constrained settings. Dried blood spot (DBS) specimens have been demonstrated to be a feasible alternative to plasma or serum for HIVDR genotyping and are more suitable for lower resource settings. There is a need for affordable HIVDR genotyping assays which can amplify HIV-1 sequences from DBS specimens, particularly those with low viral loads, at a low cost. Here, we present an in-house assay capable of reliably amplifying HIV-1 protease and partial reverse transcriptase genes from DBS specimens, which covers the complete World Health Organization 2009 list of drug resistance mutations under surveillance. DBS specimens were prepared using whole blood spiked with HIV-1 at concentrations of 10,000, 5000, 1000, and 500 copies/mL (n=30 for each concentration). Specimens were tested in triplicate. A two-step approach was used consisting of cDNA synthesis followed by nested PCR. The limit of detection of the assay was calculated to be approximately 5000 (95<!--> <!-->% CI: 3200–10,700) copies/mL for the protease gene and 3600 (95<!--> <!-->% CI: 2200–10,000) copies/mL for reverse transcriptase. The assay was observed to be most sensitive with higher viral load specimens (97.8<!--> <!-->% [95<!--> <!-->% CI: 92.2–99.7]) for both protease and reverse transcriptase at 10,000 copies/mL with performance decreasing with the use of specimens with lower viral loads (46.7<!--> <!-->% [36.1–57.5] and 60.0<!--> <!-->% [49.1–70.2] at 500 copies/mL for protease and reverse transcriptase, respectively). Ultimately, this assay presents a promising opportunity for use in resource-constrained settings. Future work should involve validation under field conditions including sub-optimal storage conditions and preparation of DBS with fingerprick blood in order to accurately reflect real-world collection scenarios.</p></div>\",\"PeriodicalId\":17663,\"journal\":{\"name\":\"Journal of virological methods\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-04-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0166093424000636/pdfft?md5=33d7e82bc47839f120e0a31109768c20&pid=1-s2.0-S0166093424000636-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of virological methods\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0166093424000636\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOCHEMICAL RESEARCH METHODS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of virological methods","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0166093424000636","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

摘要

尽管抗逆转录病毒疗法(ART)的覆盖范围不断扩大,但与坚持治疗和艾滋病毒耐药性(HIVDR)相关的挑战依然存在。高昂的 HIVDR 监测成本是在资源有限的环境中实施监测的长期挑战。事实证明,干血斑(DBS)标本可替代血浆或血清进行 HIVDR 基因分型,而且更适用于资源较少的环境。目前需要一种价格低廉的 HIVDR 基因分型检测方法,它能以低成本从 DBS 标本中扩增 HIV-1 序列,尤其是病毒载量低的标本。在此,我们介绍一种能够从 DBS 标本中可靠扩增 HIV-1 蛋白酶和部分逆转录酶基因的内部检测方法,它涵盖了世界卫生组织 2009 年监测的全部耐药突变。DBS 标本使用全血制备,HIV-1 浓度分别为 10,000、5000、1000 和 500 拷贝/毫升(每种浓度 30 人)。标本一式三份。采用的两步法包括 cDNA 合成和巢式 PCR。经计算,蛋白酶基因的检测限约为 5000(95 % CI:3200-10,700)拷贝/毫升,逆转录酶的检测限约为 3600(95 % CI:2200-10,000)拷贝/毫升。检测结果表明,在病毒载量较高的标本中,蛋白酶和逆转录酶在 10,000 拷贝/毫升时的灵敏度最高(97.8% [95 % CI:92.2-99.7]),而在病毒载量较低的标本中,灵敏度则有所下降(蛋白酶和逆转录酶在 500 拷贝/毫升时的灵敏度分别为 46.7% [36.1-57.5] 和 60.0% [49.1-70.2])。最终,这种检测方法为在资源有限的环境中使用提供了一个很好的机会。未来的工作应包括在现场条件下进行验证,包括次优储存条件和用指尖采血制备 DBS,以准确反映真实世界的采集情况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A validated in-house assay for HIV drug resistance mutation surveillance from dried blood spot specimens

Despite increasing scale-up of antiretroviral therapy (ART) coverage, challenges related to adherence and HIV drug resistance (HIVDR) remain. The high cost of HIVDR surveillance is a persistent challenge with implementation in resource-constrained settings. Dried blood spot (DBS) specimens have been demonstrated to be a feasible alternative to plasma or serum for HIVDR genotyping and are more suitable for lower resource settings. There is a need for affordable HIVDR genotyping assays which can amplify HIV-1 sequences from DBS specimens, particularly those with low viral loads, at a low cost. Here, we present an in-house assay capable of reliably amplifying HIV-1 protease and partial reverse transcriptase genes from DBS specimens, which covers the complete World Health Organization 2009 list of drug resistance mutations under surveillance. DBS specimens were prepared using whole blood spiked with HIV-1 at concentrations of 10,000, 5000, 1000, and 500 copies/mL (n=30 for each concentration). Specimens were tested in triplicate. A two-step approach was used consisting of cDNA synthesis followed by nested PCR. The limit of detection of the assay was calculated to be approximately 5000 (95 % CI: 3200–10,700) copies/mL for the protease gene and 3600 (95 % CI: 2200–10,000) copies/mL for reverse transcriptase. The assay was observed to be most sensitive with higher viral load specimens (97.8 % [95 % CI: 92.2–99.7]) for both protease and reverse transcriptase at 10,000 copies/mL with performance decreasing with the use of specimens with lower viral loads (46.7 % [36.1–57.5] and 60.0 % [49.1–70.2] at 500 copies/mL for protease and reverse transcriptase, respectively). Ultimately, this assay presents a promising opportunity for use in resource-constrained settings. Future work should involve validation under field conditions including sub-optimal storage conditions and preparation of DBS with fingerprick blood in order to accurately reflect real-world collection scenarios.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.80
自引率
0.00%
发文量
209
审稿时长
41 days
期刊介绍: The Journal of Virological Methods focuses on original, high quality research papers that describe novel and comprehensively tested methods which enhance human, animal, plant, bacterial or environmental virology and prions research and discovery. The methods may include, but not limited to, the study of: Viral components and morphology- Virus isolation, propagation and development of viral vectors- Viral pathogenesis, oncogenesis, vaccines and antivirals- Virus replication, host-pathogen interactions and responses- Virus transmission, prevention, control and treatment- Viral metagenomics and virome- Virus ecology, adaption and evolution- Applied virology such as nanotechnology- Viral diagnosis with novelty and comprehensive evaluation. We seek articles, systematic reviews, meta-analyses and laboratory protocols that include comprehensive technical details with statistical confirmations that provide validations against current best practice, international standards or quality assurance programs and which advance knowledge in virology leading to improved medical, veterinary or agricultural practices and management.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信